Drugs / BAX 855
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT01736475 | Jan 2013 → Jul 2014 | hemophilia A | Baxalta now part of Shire | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT01913405 | Dec 2013 → Sep 2016 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT01945593 | Oct 2013 → Mar 2018 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAX855 | “BAX 855, Baxalta's pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while...” PMID 26157075 ↗ Jul 2015 |
| Modality | Protein / enzyme biologic | “BAX 855, Baxalta's pegylated full-length recombinant FVIII (rFVIII)” PMID 26157075 ↗ Jul 2015 |